CROs and CDMOs become critical to global drug development

Global drug programs are getting harder to run as companies face more complex modalities, more regulatory variation, and higher manufacturing demands across regions. The article argues that integrated CRO/CDMO models can reduce handoffs, control risk, and help biopharma move faster from development to commercialization.

Why it matters: - Global drug development now requires more than trial execution in multiple countries. It depends on coordinated decisions across research, clinical, regulatory, CMC, manufacturing, quality, and supply. - Complex modalities such as peptides, oligonucleotides, and antibody-drug conjugates add technical and regulatory risk that can delay clinical supply and commercialization if not managed early. - For many biotech companies, outsourcing is one of the few practical ways to access the infrastructure and expertise needed for global programs without building every capability internally.

What happened: - The article argues that a CRO/CDMO supporting global drug development should combine modality-specific technical expertise, global regulatory experience, scalable manufacturing, mature quality systems, secure data infrastructure, and cross-region project governance. - For complex modalities, an integrated CRO/CDMO or CRDMO model can reduce handoffs, lower execution risk, and support more efficient global development. - WuXi AppTec is used as an example of that integrated model. - In a case study, WuXi AppTec mobilized its Couvet site in Switzerland to manufacture a Phase 3 clinical-stage drug that had previously been made at a partner’s internal site. - Multiple teams completed the manufacturing process transfer and scale-up in five months. - The project included equipment compatibility assessment, analytical method validation, and procurement of raw and packaging materials. - The client submitted its New Drug Application on schedule, and the drug later received approval for market launch.

The details: - Global development is harder than local-market development because clinical, regulatory, CMC, and commercialization plans must work across different healthcare systems. - A regulatory package that is sufficient for one agency may still need more evidence, analysis, or manufacturing documentation in another region. - Manufacturing is especially demanding as pipelines shift toward peptides, oligonucleotides, ADCs, and other conjugated medicines. - Oligonucleotide programs may require tight control of truncated impurities. - ADC programs may require control of the drug-to-antibody ratio, or DAR. - Critical quality attributes need to be controlled early in development and maintained through commercial supply because regulatory expectations can vary by region. - Global manufacturing must be scalable, reproducible, compliant, and adaptable to multiple regulatory authorities. - If these issues are not addressed early, clinical supply can slow, costs can rise, and regulatory uncertainty can increase. - Building GMP manufacturing infrastructure can require hundreds of millions of dollars, depending on scale, modality, and technical requirements. - That cost makes outsourcing especially relevant for pre-revenue biotech companies. - Outsourcing lets innovators reduce spending on staffing, facilities, and equipment while still accessing specialized development support. - A well-chosen partner can help companies focus internal resources on target biology, portfolio strategy, and clinical decisions. - WuXi AppTec’s Couvet site was connected to global quality procedures, digital systems, and training frameworks. - Quality leaders from other sites helped align local operations with global standards. - The example is based on WuXi AppTec’s One Global Quality System, which is designed to align quality standards and procedures across sites. - WuXi AppTec’s FAQ section says the company’s cross-region drug substance and drug product network spans Asia, Europe, and the United States. - The FAQ also says the One Global Quality System is designed to align quality standards, computerized systems, procedures, and training across sites. - The source includes a company announcement and references WuXi AppTec.

Between the lines: - The article’s core argument is that global drug development is increasingly an integration problem, not just a research problem. - The more complex the modality, the more value there is in keeping development, manufacturing, quality, and governance connected across regions. - The Couvet example suggests that operational coordination can matter as much as technical capability when a program is moving toward NDA submission and launch. - The emphasis on a single quality system reflects a broader industry need for consistency across sites, especially when regulators may evaluate the same product through different regional lenses.

What's next: - Companies developing complex therapies are likely to keep leaning on CRO/CDMO partners that can support both regional execution and global coordination. - Integrated CRDMO models may become more attractive as pipelines continue shifting toward modalities with tougher CMC and analytical demands. - For sponsors, the next decision point is whether a partner can manage the full path from early development through commercial supply without creating new handoff risk.

The bottom line: - Global drug development is increasingly won or lost on execution, and integrated CRO/CDMO partners are positioned to help companies move faster while managing technical and regulatory complexity.